Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 36: 1889-1891, 1990;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coste-Burel, M.
Right arrow Articles by Madec, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coste-Burel, M.
Right arrow Articles by Madec, Y.

Clinical Chemistry, Vol 36, 1889-1891, Copyright © 1990 by American Association for Clinical Chemistry

Study of lipoprotein particles LpAI and LpAI:AII in patients before coronary bypass surgery

M Coste-Burel, F Mainard, L Chivot, JL Auget and Y Madec
Laboratoire de Biochimie A, Hotel Dieu, CHU, Nantes, France.

Lipids, apolipoproteins, and LpAI and LpAI:AII particles were studied in 43 men (mean age 51, SD 7, years) 24 h before their coronary bypass surgery and in 54 control men (mean age 46 SD 9, years). LpAI and LpAI:AII were analyzed by electroimmunodiffusion and by a noncompetitive enzyme-linked immunoassay, respectively. Concentrations of LpAI and LpAI:AII in the bypass patients were significantly lower (P less than 0.001) than those in the controls. Apolipoprotein AI was significantly correlated with LpAI (P less than 0.001) and LpAI:AII (P less than 0.01) in controls, but only with LpAI:AII (P less than 0.001) in bypass patients. Discriminant analysis between controls and patients showed apolipoprotein AI to be the most powerful discriminant factor; the addition of LpAI and LpAI:AII did not improve discriminant power. We conclude that the determination of LpAI and LpAI:AII particles reflects metabolic disorders in patients but does not significantly influence the discrimination of such patients into risk groups.


The following articles in journals at HighWire Press have cited this article:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
G. Luc, J.-M. Bard, J. Ferrieres, A. Evans, P. Amouyel, D. Arveiler, J.-C. Fruchart, P. Ducimetiere, and on behalf of the PRIME Study Group
Value of HDL Cholesterol, Apolipoprotein A-I, Lipoprotein A-I, and Lipoprotein A-I/A-II in Prediction of Coronary Heart Disease: The PRIME Study
Arterioscler. Thromb. Vasc. Biol., July 1, 2002; 22(7): 1155 - 1161.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
L.-C. Lyu, C.-Y. Yeh, A. H Lichtenstein, Z. Li, J. M Ordovas, and E. J Schaefer
Association of sex, adiposity, and diet with HDL subclasses in middle-aged Chinese
Am. J. Clinical Nutrition, July 1, 2001; 74(1): 64 - 71.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Tilly-Kiesi, A. H. Lichtenstein, J. Joven, E. Vilella, M. C. Cheung, W. V. Carrasco, J. M. Ordovas, G. Dolnikowski, and E. J. Schaefer
Impact of Gender on the Metabolism of Apolipoprotein A-I in HDL Subclasses LpAI and LpAI:AII in Older Subjects
Arterioscler. Thromb. Vasc. Biol., December 1, 1997; 17(12): 3513 - 3518.
[Abstract] [Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Tilly-Kiesi, A. H. Lichtenstein, J. M. Ordovas, G. Dolnikowski, R. Malmstrom, M.-R. Taskinen, and E. J. Schaefer
Subjects With ApoA-I(Lys107->0) Exhibit Enhanced Fractional Catabolic Rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI With AII)
Arterioscler. Thromb. Vasc. Biol., May 1, 1997; 17(5): 873 - 880.
[Abstract] [Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
P. Alaupovic, W. J. Mack, C. Knight-Gibson, and H. N. Hodis
The Role of Triglyceride-Rich Lipoprotein Families in the Progression of Atherosclerotic Lesions as Determined by Sequential Coronary Angiography From a Controlled Clinical Trial
Arterioscler. Thromb. Vasc. Biol., April 1, 1997; 17(4): 715 - 722.
[Abstract] [Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
E. A. Brinton
Oral Estrogen Replacement Therapy in Postmenopausal Women Selectively Raises Levels and Production Rates of Lipoprotein A-I and Lowers Hepatic Lipase Activity Without Lowering the Fractional Catabolic Rate
Arterioscler. Thromb. Vasc. Biol., March 1, 1996; 16(3): 431 - 440.
[Abstract] [Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Tilly-Kiesi, Z. Qiuping, S. Ehnholm, J. Kahri, S. Lahdenpera, C. Ehnholm, and M.-R. Taskinen
ApoA-IHelsinki (Lys107->0) Associated With Reduced HDL Cholesterol and LpA-I:A-II Deficiency
Arterioscler. Thromb. Vasc. Biol., September 1, 1995; 15(9): 1294 - 1306.
[Abstract] [Full Text]

Home page
 CirculationHome page
M. Syvanne, J. Kahri, K. S. Virtanen, and M.-R. Taskinen
HDLs Containing Apolipoproteins A-I and A-II (LpA-I:A-II) as Markers of Coronary Artery Disease in Men With Non–Insulin- Dependent Diabetes Mellitus
Circulation, August 1, 1995; 92(3): 364 - 370.
[Abstract] [Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
K. Ikewaki, L. A. Zech, M. Kindt, H. B. Brewer Jr, and D. J. Rader
Apolipoprotein A-II Production Rate Is a Major Factor Regulating the Distribution of Apolipoprotein A-I Among HDL Subclasses LpA-I and LpA-I:A-II in Normolipidemic Humans
Arterioscler. Thromb. Vasc. Biol., March 1, 1995; 15(3): 306 - 312.
[Abstract] [Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
T. O'Brien, T. T. Nguyen, B. J. Hallaway, D. Hodge, K. Bailey, D. Holmes, and B. A. Kottke
The Role of Lipoprotein A-I and Lipoprotein A-I/A-II in Predicting Coronary Artery Disease
Arterioscler. Thromb. Vasc. Biol., February 1, 1995; 15(2): 228 - 231.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American Association for Clinical Chemistry.